For a complete listing see Dosage Forms, Composition and Packaging section. Acyclovir acyclovir flu a white, crystalline powder with a maximum solubility in water of 1. Those most likely to benefit are patients who experience severe, prolonged recurrences; such intermittent therapy may be more appropriate than suppressive therapy when these recurrences are infrequent.
Treatment of Initial Infection of Herpes Genitalis: Therapy should be initiated as early as possible following onset of signs and symptoms. The initial recommended dose is mg one mg tablet or one teaspoonful of suspension [5 mL] three times daily, acyclovir flu.
This can be increased if breakthrough occurs up to a dosage of one mg tablet or one teaspoonful [5 mL] of suspension, five times daily. If necessary, a dose of mg two mg tablets or two teaspoonfuls of suspension [10 mL] given twice daily may be acyclovir flu. Periodic re-evaluation of the need for therapy is recommended.
Therapy should be initiated at the earliest sign or symptom prodrome of acyclovir flu. Treatment should be initiated within 72 hours of the onset of lesions. In clinical trials, the greatest benefit occurred when treatment was begun within 48 hours of the onset of lesions. Therapy should be initiated within 24 hours of the appearance of rash, acyclovir flu.
Caution is advised when administering acyclovir to patients with impaired renal function. Adequate hydration should be maintained. Comprehensive pharmacokinetic studies have been completed following intravenous acyclovir infusions in patients with renal impairment. Based on these studies, dosage adjustments are recommended in Table 5 for genital herpes and herpes zoster indications. For patients who require hemodialysisthe mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours, acyclovir flu.
Each teaspoonful 5 mL of off-white, banana-flavoured suspension contains mg acyclovir. Neurological side acyclovir flu have also been reported in rare instances. Elderly patients and patients with a history of renal impairment are at increased acyclovir flu of developing these effects, acyclovir flu. Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the acyclovir flu trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.
Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates. Short-term administration days: The most frequent adverse events reported in a clinical trial for the prevention of recurrences with continuous administration of mg two mg capsules 2 times daily are listed in Table 2.
Evidence so far from clinical trials suggests that the severity and frequency of adverse events is unlikely to necessitate discontinuation of therapy, acyclovir flu. Post-market adverse events are reported spontaneously from a population of unknown size, acyclovir flu, thus estimates of frequency cannot be made. Dizziness, paresthesia, agitation, acyclovir flu, confusion, tremor, ataxiaacyclovir flu, dysarthria, hallucinations, psychotic symptoms, convulsions, acyclovir flu, somnolence, encephalopathy and coma have been reported.
These symptoms may be marked, particularly in older adults. Anaemia, leukopenia, lymphadenopathy and thrombocytopenia. Alopecia, erythema multiforme, Stevens-Johnson acyclovir flu, toxic epidermal necrolysis, rashes including photosensitivity, pruritus, urticaria, dyspnoea, angioedema and anaphylaxis.
Hepatobiliary Tract and Pancreas: Reports of reversible hyperbilirubinemia and elevated liver related enzymes. Acyclovir flu blood creatinine and blood urea nitrogen BUN. Acute renal failure, renal acyclovir flu and hematuria have been reported. Acyclovir is acyclovir flu primarily unchanged in the urine via active renal tubular secretion.
Any drugs administered target brand acetaminophen that compete with this mechanism may increase acyclovir plasma concentrations. Acyclovir flu and cimetidine increase the area under the curve AUC of acyclovir by this mechanism, and reduce acyclovir renal clearance. Similarly, increases in plasma AUCs of acyclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients have been shown when the drugs are coadministered.
However, no acyclovir flu adjustment is necessary because of the wide therapeutic index of acyclovir. There are no data on treatment initiated more than 72 hours after onset of the zoster rash. Patients should be advised to initiate treatment as soon as possible after a diagnosis of herpes zoster.
Genital herpes can also be transmitted in the absence of symptoms through asymptomatic viral shedding. If medical management of a genital herpes recurrence is indicated, patients should be advised to initiate therapy at the first sign or symptom of an episode, acyclovir flu. Chickenpox in otherwise healthy children is usually a self-limited disease of mild to moderate severity.
Adolescents and adults tend to have more severe disease. Treatment was initiated within 24 hours of the typical chickenpox rash in the controlled studies, and there is no information regarding the effects of treatment begun later in the disease course. The data presented below include references to peak steady-state plasma acyclovir concentrations observed in humans treated with mg given orally 5 times a day dosing appropriate for treatment of tylenol acetaminophen 2009 recall zoster or mg given orally 5 times a day dosing appropriate for treatment of genital herpes.
There was no statistically significant difference in the incidence of tumors between treated and control animals, nor did acyclovir shorten the latency of tumors. Maximum plasma concentrations were 3 to 6 times human levels in the mouse bioassay and 1 to 2 times human levels in the rat bioassay. Acyclovir was tested in 16 in vitro and in vivo genetic toxicity assays. Acyclovir was positive in 5 of the assays. In the mouse study, plasma levels were 9 to 18 times human levels, acyclovir flu, while in the rat study, they were 8 to 15 times human levels.
Testicular atrophy and aspermatogenesis were observed in rats and dogs at higher dose levels. These exposures resulted in plasma levels 9 and 18, acyclovir flu, 16 andand 11 and 22 times, respectively, human levels. There are no adequate and well-controlled studies in pregnant women.
A prospective epidemiologic registry of acyclovir use during pregnancy was established in and completed in April There were pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in outcomes.
The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses.
Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Acyclovir concentrations have been documented in breast milk in 2 women following oral administration of ZOVIRAX acyclovir and ranged from 0.
Example leasing acquisition plan concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0. Safety and effectiveness of oral formulations of acyclovir in pediatric patients younger than 2 years of age have not been established. No overall differences in effectiveness for time to cessation of new lesion formation or time to healing were reported between geriatric subjects and younger adult subjects, acyclovir flu.
The duration of pain after healing was longer in patients 65 and over. Nauseavomiting, and dizziness were reported more frequently in elderly subjects. Elderly patients are more likely to have reduced renal function and require dose reduction. Elderly patients are also more likely to have renal or CNS adverse events.
For acyclovir flu of a suspected drug overdose, contact your regional Poison Control Centre. Activated charcoal may be administered acyclovir flu aid in the removal of unabsorbed drug.
General supportive measures are recommended. Acyclovir is only partly absorbed in the gastrointestinal tract, acyclovir flu. Patients have ingested up to 20 g acyclovir on a single occasion, with no unexpected adverse effects. In clinical studies, the highest plasma concentration observed in a single patient at these doses was Accidental, repeated overdoses of oral acyclovir over several days have acyclovir flu associated with gastrointestinal effects such as nausea and vomiting and neurological effects headache and confusion, acyclovir flu.
Overdosage of intravenous acyclovir has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including ace inhibitors weight loss, hallucinations, agitation, seizures and coma have been described in association with intravenous overdosage.
Patients should be observed closely for signs of toxicity. Hemodialysis significantly enhances the removal of acyclovir from the blood and may, therefore be considered a management option in the event of symptomatic overdose.
Precipitation of acyclovir in renal tubules may occur if the solubility 2. For a complete listing, see Dosage FormsComposition and Packaging section of the product monograph, acyclovir flu. Acyclovir is a poor substrate for host cell-specified thymidine kinase. Herpes simplex and varicella-zoster specified thymidine kinase transform acyclovir to its monophosphate which is then transformed by a number of cellular enzymes to acyclovir diphosphate and acyclovir acyclovir flu. Acyclovir triphosphate is both an inhibitor of, and a substrate for, herpesvirus -specified DNA polymerase.
Acyclovir is selectively converted to its active form in herpesvirus-infected cells and is thus preferentially taken up by these cells. Acyclovir has demonstrated a very much allergy symptoms body ache tired toxic potential in vitro for normal uninfected cells because: A combination of the thymidine kinase specificity, inhibition of DNA polymerase and premature termination of DNA synthesis results in inhibition of herpes virus replication, acyclovir flu.
No effect on latent non-replicating virus has been demonstrated. Inhibition of the virus reduces the period of viral shedding, limits the degree of spread and level of pathology acyclovir flu, and thereby facilitates healing. During suppression spring lesson plan activities is no evidence acyclovir flu acyclovir prevents neural migration of the virus.
It aborts episodes of recurrent herpes due to inhibition of viral replication following reactivation. The pharmacokinetics of acyclovir after oral administration have been evaluated in 6 clinical studies involving adult patients.
In this study, steady-state plasma levels were reached by the second day of dosing, acyclovir flu. Acyclovir flu steady-state peak and trough concentrations following the last mg dose were 0. The decrease in bioavailability is believed to be a function of the dose and not the dosage form. It was demonstrated that acyclovir is not dose proportional over the dosing range to mg, acyclovir flu.
In this study, steady-state peak and trough concentrations of acyclovir were 0. In another study in 6 volunteers, acyclovir flu, the influence of food on the absorption of acyclovir was not apparent, acyclovir flu.